|
03 Nov 2020 |
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
|
|
03 Nov 2020 |
Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor
|
|
02 Nov 2020 |
InnoCare Announces Clearance by the US FDA of Phase II Clinical Trial Using orelabrutinib for the Treatment of Multiple Sclerosis
|
|
02 Nov 2020 |
Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome
|
|
02 Nov 2020 |
FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis
|
|
30 Oct 2020 |
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
|
|
30 Oct 2020 |
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
|
|
30 Oct 2020 |
LEO Pharma announces positive results of Phase 2b dose-finding study with delgocitinib cream in adult patients with mild-to-severe chronic hand eczema (CHE)
|
|
30 Oct 2020 |
European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer
|
|
29 Oct 2020 |
Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia
|
|
29 Oct 2020 |
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
|
|
29 Oct 2020 |
IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study
|
|
29 Oct 2020 |
Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia
|
|
28 Oct 2020 |
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
|
|
28 Oct 2020 |
European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options
|
|
27 Oct 2020 |
Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab
|
|
27 Oct 2020 |
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
|
|
27 Oct 2020 |
Ellodi Pharmaceuticals Announces Phase 2b Data Presented at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remission in Eosinophilic Esophagitis with APT-1011
|
|
27 Oct 2020 |
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
|
|
27 Oct 2020 |
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
|
|
27 Oct 2020 |
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
|
|
27 Oct 2020 |
Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy
|
|
27 Oct 2020 |
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
|
|
27 Oct 2020 |
eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities
|
|
27 Oct 2020 |
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
|
